Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2006-05-09
2006-05-09
Rawlings, Stephen L. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C530S300000, C530S326000, C514S010100, C514S013800
Reexamination Certificate
active
07041786
ABSTRACT:
A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
REFERENCES:
patent: 5489670 (1996-02-01), Currie et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman
patent: 5879656 (1999-03-01), Waldman
patent: 5928873 (1999-07-01), Waldman
patent: 5969097 (1999-10-01), Wiegand et al.
patent: 2002/0128176 (2002-09-01), Forssmann et al.
patent: 2005/0032684 (2005-02-01), Cetin et al.
patent: WO 02/098912 (2002-12-01), None
patent: WO 02/098912 (2002-12-01), None
Shailubhai K, et al. Clinical Cancer Res. (Proc. 1999 AACR NCI EORTC International Conference) 1999; 5 (Suppl.); Abstract #0734.
Pitari GM, et al. Proc. Natl. Acad. Sci. USA. Jul. 3, 2001; 98 (14): 7846-51.
Natham A, et al. Bioconjug Chem. Jan.-Feb.; 1993 4 (1): 54-62.
Caliceti P, et al. Biochimica et Biophysica Acta. 2001; 1528: 177-86.
Hinds K, et al. Bioconjug. Chem. 2000; 11: 195-201.
Forte LR. Regul. Pept. May 31, 1999; 81 (1-3): 25-39.
Hikada Y, et al. Biochemistry. 1998; 37: 8498-507.
Hikada Y, et al. J. Biol. Chem. Aug 18, 2000; (33); 25155-62.
Klodt J, et al. J. Pept. Res. Sep. 1997; 50 (3): 222-30.
Garcia KC, et al. J. Biol. Chem. Oct 25, 1993; 268 (30): 22397-401.
Baxter GF. Basic Res. Cardiol. Mar. 2004; 99 (2): 71-5.
Takada I, et' al. Mol. Endocrinol. 2000; 14 (5): 733-40.
Bergers G, et al. Current Opinion in Genetics and Development. 2000; 10: 120-7.
Gura T. Science. 1997; 278: 1041-2.
Shailubhai K. Curr. Opin. Drug Discov. Devel. Mar. 2002; 5 (2): 261-8.
Shailubhai et al., “Uroguanylin Treatment Suppresses Polyp Formation in the Apc Min/+ Mouse and Induces Apoptosis in Human Colon Adenocarcinoma Cells via Cyclic GMP”Cancer Research 60(Sep. 15, 2000) 5151-5157.
Carrithers et al., “Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues”Proc. Natl. Acad. Sci. USA93 (Dec. 1996) 14827-14832.
Hill et al., “Analysis of the human guanylin gene and the processing and cellular localization of the peptde”Proc. Natl. Acad. Sci. USA92 (Mar. 1995) 2046-2050.
Hamra et al., “Uroguanylin: Structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase”Proc. Natl. Acad. Sci. USA90 (Nov. 1993) 10464-10468.
De Sauvage et al., “Precursor structure, expression and tissue distribution of human guanylin”Proc. Natl. Acad. Sci. USA89 (Oct. 1992) 9089-9093.
Currie et al., “Guanylin: An endogenous activator of intestinal guanylate cyclase”Proc. Natl. Acad. Sci. USA89 (Feb. 1992) 947-951.
Sindice, et al., Journal of Biological Chemistry, 277:17758-17764 (2002).
Jacob Gary S.
Nikiforovich Gregory
Shailubhai Kunwar
Callisto Pharmaceuticals
Elrifi Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rawlings Stephen L.
LandOfFree
Guanylate cyclase receptor agonists for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Guanylate cyclase receptor agonists for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Guanylate cyclase receptor agonists for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3553487